BCompany · Healthtech & Bio
Biohope
Biohope is a Madrid-based, commercial-stage biomedical company developing precision-medicine in vitro diagnostic (IVD) tools for chronic inflammatory and autoimmune conditions. Its flagship product, Immunobiogram®, is a CE-marked, ISO 13485-certified functional cellular assay that personalizes immunosuppressive therapy for kidney transplant patients by measuring individual immune cell response to different drugs. Founded in 2015, the company has received EU Horizon 2020 non-dilutive grants and regional Madrid innovation funding alongside private investment.
Founded
2015
Founders
1
News
0
Rounds
0
Investors
3
SectorsPrecision Medicine, In Vitro Diagnostics, Immunology, Transplant Diagnostics, Autoimmune Diseases
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Profile updated 31 Jul 2026
Founders
I
Isabel Portero
Founder & CSO
Global models 5
GGrail
United States · grail.com ↗
Blood-based precision diagnostic testing for early disease detection, the same core model of a proprietary blood assay driving personalized clinical decisions.
$2.0BComparable
TTempus AI
United States · www.tempus.com ↗
Precision-medicine diagnostics platform that uses molecular/clinical data to personalize patient treatment, mirroring Biohope's personalize-therapy-via-diagnostics model.
$1.3BComparable
GGuardant Health
United States · guardanthealth.com ↗
Liquid-biopsy diagnostic tests that guide personalized treatment decisions, the same precision-diagnostics-to-therapy-selection model.
$550MComparable
FFreenome
United States · www.freenome.com ↗
Blood-based multiomics diagnostic platform for personalized disease detection, similar blood-test-driven precision medicine approach.
$524MComparable
CCareDx
United States · caredx.com ↗
The closest direct comparable: blood-based diagnostic tests (AlloSure/AlloMap) that personalize immunosuppressive therapy for transplant patients.
$138MComparable
Investors 3
Funding rounds
No announced rounds on record.
News & media
No coverage on record yet.


